|Bid||39.66 x 800|
|Ask||39.68 x 3000|
|Day's range||39.51 - 40.08|
|52-week range||25.04 - 43.16|
|Beta (5Y monthly)||0.71|
|PE ratio (TTM)||N/A|
|Earnings date||03-May-2020 - 07-May-2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||37.70|
NEW YORK, April 02, 2020 -- Mobile Mini, Inc. (MINI) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of.
Following the announcement of the agreement to pass the historic stimulus bill, we look into four MedTech stocks that stand to gain from the same.
QIAGEN receives U.S. FDA EUA for QIAstat-Dx test kit, first and only syndromic solution integrating detection of SARS-CoV-2 coronavirus
Here are some MedTech stocks which are steadily inching toward a trend reversal after registering record declines over the past few weeks.
The global financial markets are currently witnessing one of the worst periods since the Great Depression due to the coronavirus-led crisis.
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Qiagen N.V. (NYSE: QGEN) resulting from allegations that Qiagen may have issued materially misleading business information to the investing public.
NEW YORK, March 24, 2020 -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders..
The test kit, QIAstat-Dx Respiratory SARS-CoV-2 Panel, requires less than one minute for sample preparation and can deliver results in about one hour, the company said. Shipments come under a new policy laid out by the U.S. Food and Drug Administration earlier this month to help accelerate the availability of coronavirus diagnostic tests, developed by laboratories and commercial manufacturers during the public health emergency. The company intends to submit an application for the related Emergency Use Authorization to the FDA this week, Qiagen said.
QIAGEN releases QIAstat-Dx test kit to the U.S. as first syndromic test for detection of SARS-CoV-2 coronavirus under new FDA policy
NEW YORK, March 23, 2020 -- Neon Therapeutics, Inc. (NTGN) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale.
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has obtained CE marking for its newly developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test to be sold as an in vitro diagnostic ("IVD") for the detection of SARS-CoV-2.
QIAGEN dramatically ramping up global production capacity for RNA extraction kits for use in detection of SARS-CoV-2 coronavirus
CENTOGENE N.V. (CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced changes to its Supervisory Board. Mr. Jacob Kaluski, a member of the Supervisory Board since 2014, has decided to resign from his office with effect from March 16, 2020. The Supervisory Board would like to thank Mr. Kaluski for his valuable contributions to CENTOGENE’s success over the past six years, during which CENTOGENE has developed into a leading contributor in the battle against rare diseases.
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Qiagen N.V.
QIAGEN (QGEN) receives support from the government to accelerate the development of the QIAstat-Dx test kit to detect the coronavirus causing virus.